Actelion Could Succumb To Big Pharma's Charms
News that Europe’s largest biotech Actelion is in preliminary discussions with Johnson & Johnson about a transaction has been viewed favourably by investors, and could see the return of mega-merger activity to other big pharma companies.
You may also be interested in...
4Q Pharma Results Preview: J&J, Novartis, Bristol, Celgene, Biogen
Scrip offers some key points to watch for as Johnson & Johnson and Novartis kick off the big pharma full-year presentations Jan. 24, with Bristol-Myers Squibb, Celgene and Biogen Idec finishing off the first week of earnings season.
Was Sanofi’s Offer One That Actelion Could Refuse? J&J Back At Bargaining Table
Johnson & Johnson is back at the M&A bargaining table with Actelion after walking away from negotiations a week ago, raising questions about whether Sanofi’s deal terms were harder to digest than J&J’s.
Gilead Coming To The End Of HCV Road With Triple-Drug Regimen
Gilead reported an expected and continued sales decline in HCV – an area in which the company soon will be done with R&D, since unmet needs have been filled or will be soon by drug regimens from Gilead and its competitors. The company is hunting new assets, but taking a disciplined approach on price and quality.